Abstract Number: 136 • 2014 ACR/ARHP Annual Meeting
Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis
Background/Purpose Serological biomarkers specifically reflecting pathological processes may have added value in assessing joint inflammation in rheumatoid arthritis (RA). Calprotectin (S100A8/9 protein) has been demonstrated…Abstract Number: 2813 • 2014 ACR/ARHP Annual Meeting
Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients
Background/Purpose : Morning stiffness may not be specifically queried by rheumatologists in the course of their regular interactions with rheumatoid arthritis (RA) patients. This analysis…Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting
Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis
Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span. MicroRNA 155 (miR155) is particularly implicated in…Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting
Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…Abstract Number: 1426 • 2014 ACR/ARHP Annual Meeting
Periodontal disease and Clinical Activity of Rheumatoid Arthritis Patients
Background/Purpose: Although several studies have suggested the association between periodontitis, infection by Porphyromona gingivalisand Rheumatoid Arthritis disease activity, its relationship with periodontal disease, oral and…Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting
Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting
Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort
Background/Purpose: Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…Abstract Number: 128 • 2014 ACR/ARHP Annual Meeting
A Rapid 4- Joint Ultrasonographic Score to Daily Monitoring Disease Activity in Patients with Rheumatoid Arthritis: Validity and Sensitivity to Change
Background/Purpose Ultrasound has demonstrated to be a sensitivity and specific tool to assess patients with Rheumatoid Arthritis (RA). However, the feasibility of this technology in…Abstract Number: 2636 • 2014 ACR/ARHP Annual Meeting
Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE)
Background/Purpose SLE patients have an increased risk of cardiovascular disease (CVD). Vitamin D deficiency has been associated with both CVD risk factors and subclinical CVD…Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting
Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGAAbstract Number: 1040 • 2014 ACR/ARHP Annual Meeting
Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention
Background/Purpose: IL-16 is a chemoattractant factor that evokes massive infiltration of mononuclear cells in the synovial tissue in patients rheumatoid arthritis (RA). IL-16 concentrations are…Abstract Number: 679 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Dosing and Disease Activity in a Large Multi-Racial Lupus Cohort
Background/Purpose: Treatment with hydroxychloroquine (HCQ) is recommended for all patients with lupus nephritis to prevent further damage and reduce disease manifestations. Some studies suggest…
- « Previous Page
- 1
- …
- 92
- 93
- 94
- 95
- 96
- …
- 102
- Next Page »